Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

eosinophilic

- PMLiVE

EMA: Lack of evidence for Ebola treatments

Not enough data to draw conclusions on effectiveness of experimental drugs

EU flag

EC: Search for Rasi’s replacement could take six months

Commission tells PMLiVE process could still be impacted by the procedure's complexity

- PMLiVE

Early approval for Amgen’s breakthrough leukaemia drug

32% of patients in remission after at least four weeks of Blincyto infusion

- PMLiVE

Novartis’ heart failure drug on EMA’s fast track

Candidate is the first cardiovascular drug to get accelerated review in the EU

- PMLiVE

Teva board elects Yitzhak Peterburg as chairman

He succeeds Phillip Frost

- PMLiVE

BMS’ daclatasvir scuppered by decision to drop companion drug

FDA denies approval due to discontinuation of asunaprevir development

- PMLiVE

FDA adds rare brain infection link to Tecfidera labelling

Biogen Idec’s MS drug gets safety warning

- PMLiVE

Amgen/AZ confirm brodalumab psoriasis filing in 2015

Drug demonstrates greater effectiveness than J&J’s Stelara

Novartis day

FDA needs more time to review Novartis’ cancer drug

Panobinostat is being investigated for use in multiple myeloma

EU flag

Orphan drugs in latest CHMP recommendations

EMA advisers back new products from Genzyme, Boehringer and others

- PMLiVE

EMA recommends two AbbVie treatments for hepatitis C

Exviera and Viekirax backed for use in Europe

- PMLiVE

EMA appoints Luc Vanheel as head of administration

He joins with immediate effect

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links